Ubrogepant inhibits the signaling pathway between G-protein-coupled receptors (GPCRs) and G proteins.
Molecular Weight
549.54
Molecular Formula
C29H26F3N5O3
Form
Lyophilized powder
Purity
>98%
Applications
Ubrogepant can be studied for its effect on blocking the CGRP receptors, which are involved in the transmission of pain signals during a migraine attack.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
